The Justice Department has been looking into allegations involving Epogen, Enbrel and Aranesp. Amgen's ($AMGN) long-brewing settlement with the U.S. Justice ...

This leaflet answers some common questions about Aranesp (darbepoetin alfa). It does not contain all the available information. It does not take the place of talking to your doctor, nurse or ...

LOS ANGELES (Reuters) - Amgen Inc. said on Monday that 48.5 percent of cancer patients not undergoing chemotherapy or radiation who received its anemia drug Aranesp in a clinical trial died compared ...

Amgen executives detailed their alleged Aranesp "overfill" kickback scheme in a set of PowerPoint slides and Excel spreadsheets, according to a lawsuit filed by the New York State Attorney General.

NEW YORK, April 19 (Reuters) - Amgen Inc.'s. anemia drug Aranesp showed no increased risk of death compared to a placebo in a study of small-cell lung cancer patients undergoing chemotherapy, sending ...

Darbepoetin alfa 10mcg/0.4mL, 25mcg/0.42mL, 40mcg/0.4mL, 60mcg/0.3mL, 100mcg/0.5mL, 150mcg/0.3mL, 200mcg/0.4mL, 300mcg/0.6mL, 500mcg/mL; per prefilled syringe; for IV ...

The potential risk of stroke has been listed on Aranesp's label since the drug was approved in 2001, but "we will definitely update the label" because of the new study's results, he said. Aranesp did ...

The study showed patients treated with Aranesp had a reduction in the number of red blood cell transfusions Amgen announced positive results from the Phase 3 ARCADE study evaluating Aranesp ...

Amgen is the subject of the FDA’s latest untitled letters. The regulator’s Office of Prescription Drug Promotion (OPDP) knocked the company for a mailer promoting it its chronic kidney disease anemia ...

THOUSAND OAKS, Calif., (March 27, 2006) – Amgen (NASDAQ: AMGN), the world's largest biotechnology company, today announced the U.S. Food and Drug Administration (FDA) has approved every-three-week ...

As expected, the European Commission gave its marketing nod to Aranesp and Neulasta, the strong-selling U.S. oncology products from Amgen Inc. The company's stock (NASDAQ:AMGN) closed Wednesday at $45 ...